Quanterix

Advances in blood-based biomarkers are transforming Alzheimer's disease research, but standard venous draws and lab requirements limit broad accessibility—especially in remote or resource-constrained settings. A recent study from the University of Gothenburg, published in Alzheimer’s & Dementia, demonstrates the potential of Dried Plasma Spot sampling combined with ultrasensitive Simoa® detection as a reliable, stable, and scalable method for AD biomarker analysis. This approach could pave the way for decentralized, early detection and monitoring of Alzheimer’s disease. Read the full study highlight to learn more: https://lnkd.in/ewhfjbwf #AlzheimersDisease #Neurodegeneration #DriedPlasmaSpot

#News New evidence flips the script on whiplash: It’s not just musculoskeletal — early nerve injury could be the key to long-term pain. This study challenges the conventional view of WADII (Whiplash-Associated Disorder Grade II) as purely musculoskeletal by identifying signs of acute axonal injury. Elevated serum NfL levels and persistent sensory deficits indicated underlying nerve involvement, even in the absence of overt nerve damage on standard diagnostics. Notably, 65% of participants exhibited neuropathic pain early on, with one-third still symptomatic after six months. A simple bedside test, cutaneous hypoaesthesia at the index finger, emerged as a potential predictor of long-term pain. These findings highlight the potential of NfL and bedside sensory testing to better identify individuals at risk and inform early, targeted interventions. Read more: https://lnkd.in/e7NvTNMy

The countdown is on for Alzheimer's Association®’s International Conference® 2025! This summer, we'll be exhibiting at the world’s leading conference for #dementia science, uniting researchers and clinicians to share breakthroughs in diagnosis, treatment, and care for Alzheimer’s and other dementias. Learn more: https://lnkd.in/evj6nqTu #alzheimersdisease #neuro

With spring in full motion, let's take a closer look at IFN-α: a key #cytokine in immune defense. Interferon-alpha (IFN-α) is a type I cytokine vital to innate immunity — activating antiviral defenses and rallying immune cells like NK cells and macrophages. With 17+ subtypes, precise detection is critical. The Simoa® IFN-α Multi-Subtype Assay quantifies this key cytokine at ultra-low levels, empowering research in #infections, #autoimmunity & #oncology. Learn more about IFN-α: https://lnkd.in/e33PPK7D

ARUP Laboratories now offers a plasma test for pTau 217 to aid in the detection of Alzheimer’s disease pathology. Validated with samples from Eli Lilly and Company’s Phase 3 TRAILBLAZER-ALZ 2 trial, this test is minimally invasive and more accessible than other types of diagnostic testing. https://ow.ly/8ucJ50VEMFp

#News This study shares that amyloid-β and phosphorylated tau are the key #biomarkers and predictors of Alzheimer’s Disease--even before symptoms appear--proving invaluable for early diagnosis and progression estimation. Read how these biofluid-based biomarkers may offer a sensitive diagnostic tool for #AD and how comorbidities such as cardiovascular disease, obesity, depression, and diabetes impact patient care: https://lnkd.in/emSixXAH

The Alzheimer’s biomarker detection revolution is here. Dried Blood Spot (#DBS) and Dried Plasma Spot (#DPS) testing are transforming Alzheimer’s disease research by enabling minimally invasive, cost-effective blood #biomarker detection. Powered by ultra-sensitive Simoa® technology, recent studies confirm the feasibility of measuring key neurological biomarkers—such as NfL, GFAP, and p-Tau 217—from simple finger-prick samples. With the potential for at-home self-collection and stable long-term storage, DPS testing paves the way for broader accessibility in AD screening and monitoring. Read our latest app note to discover how this breakthrough could reshape the future of neurological diagnostics: https://lnkd.in/ex-N7t_Z #alzheimersdisease

At Quanterix, we know that delivering quality isn’t just a goal — it’s what sets us apart. From innovation in early disease detection to building a culture rooted in collaboration and growth, every day at Quanterix is a chance to make a real impact, and quality is at the heart of it all. Ernest Ansah, our Director of Quality Assurance, is proud to help ensure the highest standards as we work together to shape the future of healthcare. Curious about joining us? Explore our open roles here: https://lnkd.in/ek8yRgX5 #CompanyCulture

April is National Stress Awareness Month, a time to recognize how #stress impacts both physical and mental well-being. A recent study using Simoa® technology reveals that early-life stress correlates with structural brain changes, poorer cognitive function, and #biomarkers linked to Alzheimer’s disease. These findings highlight the importance of early detection and intervention strategies for those at higher risk of neurodegenerative disorders. Explore the connection between early-life stress and long-term brain health in one of our latest blogs: https://lnkd.in/evxVCnZz We hope you take extra time this month to prioritize self-care and explore effective ways to manage stress. Finding healthy coping strategies can make a significant difference in our overall well-being.

Cancers, neurological, autoimmune, and inflammatory disorders are notoriously hard to diagnose early. Their subtle progression can easily be mistaken for other conditions, delaying treatment. That’s where IL-17A comes in. This key pro-inflammatory cytokine plays a central role in triggering inflammation, immune cell activation, and tissue damage, driving disease progression. Measuring IL-17A is crucial for developing targeted therapies, especially in oncology and inflammatory disorders. The Simoa® IL-17A Advantage PLUS assay offers ultra-sensitive detection, making early detection and monitoring treatment more precise than ever. Thousands of studies validate Simoa® technology in detecting biomarkers for early diagnosis, prognosis, and treatment of complex conditions—helping to understand the molecular mechanisms behind IL-17A-driven inflammation and its role in disease progression. Learn more: https://lnkd.in/ePcpdaK7 #Biomarkers #AutoimmuneDiseases #Oncology